A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

Abroad (travel likely)RecruitingPHASE1

Conditions

B-cell Non-Hodgkin Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Ruijin Hospital, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Pei miao Zhang) · pm.zhang@wiseon.cn · 010-57593072

Study leads

Wei li Zhao
Principal Investigator
Ruijin Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL

Non-hodgkin Lymphoma · Refractory Lymphoma · Chimeric Antigen Receptor T-cell

Abroad (travel likely)RecruitingPHASE1

Xiamen, China

A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Relapsed B-cell Non-Hodgkin Lymphoma · Refractory B-cell Non-Hodgkin Lymphoma

Abroad (travel likely)RecruitingPHASE1

Beijing, China · Beijing, China

A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

Acute Lymphoblastic Leukemia · Non-hodgkin Lymphoma

Abroad (travel likely)RecruitingEARLY_PHASE1

Hangzhou, China

A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma

Recurrent B-Cell Non-Hodgkin Lymphoma · Recurrent Multiple Myeloma · Refractory B-Cell Non-Hodgkin Lymphoma

Abroad (travel likely)Recruiting

Columbus, United States